A Phase 3 interventional study of Sarilumab and Sulfasalazine in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 40 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-01-30.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 11th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 15th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2007; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 88 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
36 studies in Arthritis, Rheumatoid by Sanofi: 2 open now, 2 under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is the 18th largest by enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2015, is one of 9 in phase 3, and was the 25th registered.
Sanofi’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 36 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To document the long-term safety of sarilumab added to non-methotrexate (non-MTX) disease-modifying antirheumatic drugs (DMARDs) or as monotherapy.
Secondary Objective:
To document the long term efficacy of sarilumab added to non-MTX DMARDs or as monotherapy.
Total study duration was up to 62 weeks: Up to 4-week screening period, 52-week treatment period, and 6-week post-treatment follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of rheumatoid arthritis (RA), according to the American College of Rheumatology/The European League Against Rheumatism (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria with >=3 months disease duration.
Moderately to severely active RA defined as:
For the combination stratum:
Participants who had continuous treatment with non-biologic DMARDs other than MTX for at least 12 weeks prior to the randomization and on a stable dose for a minimum of 6 weeks prior to screening.
For the monotherapy stratum:
Participants who per investigator judgment were any of inappropriate, intolerant or inadequate to MTX treatment.
Exclusion criteria:
Participants \<20 years of age. Prior treatment with tumor necrosis factor (TNF) antagonists or any other RA-directed biologic agents without the appropriate off-drug period prior to screening.
Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
Drug: Sarilumab · Drug: Sulfasalazine · Drug: Leflunomide · Drug: Bucillamine · Drug: Tacrolimus · Drug: Mizoribine
Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
Drug: Sarilumab · Drug: Sulfasalazine · Drug: Leflunomide · Drug: Bucillamine · Drug: Tacrolimus · Drug: Mizoribine
Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.
Drug: Sarilumab
Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.
Drug: Sarilumab
Pharmaceutical form:solution
Also known as: SAR153191 (REGN88)
Pharmaceutical form: Tablet Route of administration: Oral
Pharmaceutical form: Tablet Route of administration: Oral
Pharmaceutical form: Tablet Route of administration: Oral
Pharmaceutical form: Capsule Route of administration: Oral
Pharmaceutical form: Tablet Route of administration: Oral
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received IMP and did not necessary have to had a causal relationship with treatment. All AEs that occurred from the first dose of the IMP administration up to 6 weeks after last dose of treatment (up to Week 58) were considered as TEAEs. SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. TEAEs included both SAEs and non-SAEs.
Time frame: Baseline up to Week 58
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP) supine: \<=95 mmHg and decrease from baseline (DFB) \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB ≥10 mmHg * SBP (Orthostatic): \<=-20 mmHg * DBP (Orthostatic): \<=-10 mmHg * Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB
Time frame: Baseline up to Week 58
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
Criteria for potentially clinically significant ECG abnormalities: * PR Interval: \>200 milliseconds (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QT Interval: \>500 ms * QTc Bazett (QTc B): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms, IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms
Time frame: Baseline up to Week 58
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters
Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female\[F\]); \>=185 g/L (M) or \>=165 g/L (F); DFB \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<50 Giga/L; \>=50 and \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \<0.5 Giga/L; \>=0.5 Giga/L and \<lower limit of normal (LLN); \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)
Time frame: Baseline up to Week 58
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Hemoglobin A1c (HbA1c): \>8% * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L
Time frame: Baseline up to Week 58
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes
Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L
Time frame: Baseline up to Week 58
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters
Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min * Blood urea nitrogen: \>=17 mmol/L * Uric acid: \<120 micromol/L; \>408 micromol/L
Time frame: Baseline up to Week 58
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN * Conjugated bilirubin(CBILI): \>1.5 ULN * Unconjugated bilirubin: \>1.5 ULN * ALT \>3 ULN and TBILI \>2 ULN * CBILI \>35% TBILI and TBILI \>1.5 ULN * Albumin: \<=25 g/L
Time frame: Baseline up to Week 58
Percentage of Participants Achieving American College of Rheumatology (ACR) 20, 50 and 70 Responses at Week 52
ACR response is a composite rating scale that includes 7 variables: tender joints count (TJC \[68 joints\]); swollen joints count (SJC \[66 joints\]); levels of an acute phase reactant (high sensitivity C-reactive protein \[hs-CRP level\]); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by Health Assessment Question-Disability Index \[HAQ-DI\], with scoring range of 0 \[better health\] - 3 \[worst health\]). ACR20/50/70 response is defined as at least 20/50/70% improvement in both TJC and SJC, and at least 20/50/70% improvement in at least 3 of the 5 other assessments, respectively.
Time frame: Week 52
Change From Baseline at Week 52 in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP)
DAS28-CRP is a composite score that contains 4 variables: TJC (based on 28 joints), SJC (based on 28 joints), participant's assessment of general health on VAS (range 0 \[very well\] to 100 mm \[extremely bad\]) and CRP (mg/L). DAS28-CRP total score ranges from 2-10 with a lower score indicating less disease activity. A DAS28-CRP above 5.1 indicates high disease activity, whereas below 3.2 indicates low disease activity and below 2.6 as disease remission.
Time frame: Baseline, Week 52
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52
HAQ-DI assessed the degree of difficulty participants experienced in 8 daily living activity domains during a week: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consisted of 2-3 items. Each items's difficulty was scored from 0-3 (0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do). Overall HAQ-DI score was computed as the sum of domain scores divided by the number of domains answered, providing a score from 0-3. Low scores denoted improvement of disability/lower degree of domain difficulty.
Time frame: Baseline, Week 52
This study was conducted at 40 centers in Japan. A total of 117 participants were screened between 23 February 2015 and 9 September 2015, 26 of whom were screen failures.
| Milestone | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| Started | 15 | 15 | 30 | 31 |
| Completed | 13 | 9 | 27 | 30 |
| Not completed | 2 | 6 | 3 | 1 |
| Withdrew: Adverse event | 2 | 5 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received IMP and did not necessary have to had a causal relationship with treatment. All AEs that occurred from the first dose of the IMP administration up to 6 weeks after last dose of treatment (up to Week 58) were considered as TEAEs. SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. TEAEs included both SAEs and non-SAEs.
| participants | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| Any TEAE | 14 | 13 | 25 | 28 |
| SAE | 0 | 3 | 1 | 2 |
Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP) supine: \<=95 mmHg and decrease from baseline (DFB) \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB ≥10 mmHg * SBP (Orthostatic): \<=-20 mmHg * DBP (Orthostatic): \<=-10 mmHg * Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB
| participants | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| SBP (supine) <=95 mmHg and DFB >=20 mmHg | 0 | 0 | 0 | 0 |
| SBP (supine) >=160 mmHg and IFB >=20 mmHg | 1 | 1 | 1 | 1 |
| DBP (supine) <=45 mmHg and DFB >=10 mmHg | 0 | 0 | 0 | 0 |
| DBP (supine) >=110 mmHg and IFB >=10 mmHg | 0 | 0 | 0 | 0 |
| SBP (orthostatic) <=-20 mmHg | 8 | 5 | 5 | 9 |
| DBP (orthostatic) <=-10 mmHg | 3 | 3 | 5 | 10 |
| HR (supine) <=50 bpm and DFB >= 20 bpm | 0 | 0 | 1 | 1 |
| HR (supine) >=120 bpm and IFB >=20 bpm | 0 | 0 | 0 | 0 |
| Weight >=5% DFB | 1 | 1 | 2 | 0 |
| Weight >=5% IFB | 3 | 2 | 12 | 7 |
Criteria for potentially clinically significant ECG abnormalities: * PR Interval: \>200 milliseconds (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QT Interval: \>500 ms * QTc Bazett (QTc B): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms, IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms
| participants | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| PR >200 ms | 0 | 0 | 0 | 1 |
| PR >200 ms and IFB >=25% | 0 | 0 | 0 | 0 |
| PR >220 ms | 0 | 0 | 0 | 1 |
| PR >220 ms and IFB >=25% | 0 | 0 | 0 | 0 |
| PR >240 ms | 0 | 0 | 0 | 0 |
| PR >240 ms and IFB >=25% | 0 | 0 | 0 | 0 |
| QRS >110 ms | 0 | 2 | 0 | 1 |
| QRS >110 ms and IFB >=25% | 0 | 0 | 0 | 0 |
| QRS >120 ms | 0 | 2 | 0 | 0 |
| QRS >120 ms and IFB >=25% | 0 | 0 | 0 | 0 |
| QT >500 ms | 0 | 0 | 0 | 1 |
| QTc B >450 ms | 2 | 1 | 6 | 10 |
| QTc B >480 ms | 0 | 1 | 0 | 1 |
| QTc B >500 ms | 0 | 0 | 0 | 0 |
| QTc B IFB >30 and <=60 ms | 0 | 1 | 2 | 1 |
| QTc B IFB >60 ms | 0 | 0 | 0 | 0 |
| QTc F >450 ms | 2 | 1 | 2 | 6 |
| QTc F >480 ms | 0 | 0 | 0 | 1 |
| QTc F >500 ms | 0 | 0 | 0 | 0 |
| QTc F IFB >30 and <=60 ms | 0 | 0 | 0 | 0 |
| QTc F IFB >60 ms | 0 | 0 | 0 | 0 |
Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female\[F\]); \>=185 g/L (M) or \>=165 g/L (F); DFB \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<50 Giga/L; \>=50 and \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \<0.5 Giga/L; \>=0.5 Giga/L and \<lower limit of normal (LLN); \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)
| participants | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| Hemoglobin <=115 g/L (M) or <=95 g/L (F) | 0 | 1 | 1 | 3 |
| Hemoglobin >=185 g/L (M) or >=165 g/L (F) | 0 | 0 | 0 | 0 |
| Hemoglobin DFB >=20 g/L | 0 | 0 | 0 | 2 |
| Hematocrit <=0.37 v/v (M) or <=0.32 v/v (F) | 0 | 3 | 2 | 6 |
| Hematocrit >0.55 v/v (M) or >=0.5 v/v (F) | 0 | 0 | 0 | 0 |
| RBC >=6 Tera/L | 0 | 0 | 0 | 0 |
| Platelets <50 Giga/L | 0 | 0 | 0 | 0 |
| Platelets >=50 and <100 Giga/L | 1 | 1 | 1 | 0 |
| Platelets >=700 Giga/L | 0 | 0 | 0 | 0 |
| WBC <3.0 Giga/L (NB) or <2.0 Giga/L (B) | 6 | 9 | 7 | 9 |
| WBC >=16.0 Giga/L | 0 | 0 | 0 | 0 |
| Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B) | 8 | 11 | 8 | 13 |
| Neutrophils <1.0 Giga/L | 5 | 3 | 2 | 4 |
| Lymphocytes <0.5 Giga/L | 0 | 0 | 0 | 1 |
| Lymphocytes >=0.5 Giga/L and <LLN | 3 | 4 | 3 | 8 |
| Lymphocytes >4.0 Giga/L | 0 | 1 | 0 | 0 |
| Monocytes >0.7 Giga/L | 1 | 0 | 3 | 2 |
| Basophils >0.1 Giga/L | 1 | 0 | 0 | 5 |
| Eosinophils >0.5 Giga/L or >ULN (ULN >=0.5 Giga/L) | 0 | 0 | 2 | 2 |
ACR response is a composite rating scale that includes 7 variables: tender joints count (TJC \[68 joints\]); swollen joints count (SJC \[66 joints\]); levels of an acute phase reactant (high sensitivity C-reactive protein \[hs-CRP level\]); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by Health Assessment Question-Disability Index \[HAQ-DI\], with scoring range of 0 \[better health\] - 3 \[worst health\]). ACR20/50/70 response is defined as at least 20/50/70% improvement in both TJC and SJC, and at least 20/50/70% improvement in at least 3 of the 5 other assessments, respectively.
| percentage of participants | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| ACR20 | 73.3 | 40.0 | 76.7 | 74.2 |
| ACR50 | 60.0 | 33.3 | 56.7 | 54.8 |
| ACR70 | 53.3 | 26.7 | 26.7 | 25.8 |
DAS28-CRP is a composite score that contains 4 variables: TJC (based on 28 joints), SJC (based on 28 joints), participant's assessment of general health on VAS (range 0 \[very well\] to 100 mm \[extremely bad\]) and CRP (mg/L). DAS28-CRP total score ranges from 2-10 with a lower score indicating less disease activity. A DAS28-CRP above 5.1 indicates high disease activity, whereas below 3.2 indicates low disease activity and below 2.6 as disease remission.
| units on a scale | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| Change From Baseline at Week 52 in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP) | -2.90 ± 1.06 | -2.47 ± 0.84 | -2.62 ± 1.12 | -2.64 ± 1.35 |
HAQ-DI assessed the degree of difficulty participants experienced in 8 daily living activity domains during a week: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consisted of 2-3 items. Each items's difficulty was scored from 0-3 (0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do). Overall HAQ-DI score was computed as the sum of domain scores divided by the number of domains answered, providing a score from 0-3. Low scores denoted improvement of disability/lower degree of domain difficulty.
| units on a scale | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52 | -0.52 ± 0.45 | -0.34 ± 0.60 | -0.48 ± 0.58 | -0.38 ± 0.34 |
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Hemoglobin A1c (HbA1c): \>8% * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L
| participants | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| Glucose <=3.9 mmol/L and <LLN | 0 | 0 | 1 | 1 |
| Glucose >=11.1 mmol/L (unfas) or >=7 mmol/L (fas) | 0 | 1 | 0 | 2 |
| HbA1c >8% | 0 | 0 | 0 | 1 |
| Total Cholesterol >=6.2 mmol/L | 6 | 7 | 12 | 13 |
| Total Cholesterol >=7.74 mmol/L | 1 | 1 | 1 | 2 |
| LDL Cholesterol >=4.1 mmol/L | 1 | 3 | 6 | 3 |
| LDL Cholesterol >=4.9 mmol/L | 0 | 1 | 2 | 1 |
| Triglycerides >=4.6 mmol/L | 0 | 0 | 0 | 1 |
| Triglycerides >=5.6 mmol/L | 0 | 0 | 0 | 1 |
Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L
| participants | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| Sodium <=129 mmol/L | 0 | 0 | 0 | 0 |
| Sodium >=160 mmol/L | 0 | 0 | 0 | 0 |
| Potassium <3 mmol/L | 0 | 0 | 0 | 0 |
| Potassium >=5.5 mmol/L | 0 | 0 | 0 | 0 |
| Chloride <80 mmol/L | 0 | 0 | 0 | 0 |
| Chloride >115 mmol/L | 0 | 0 | 0 | 0 |
Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min * Blood urea nitrogen: \>=17 mmol/L * Uric acid: \<120 micromol/L; \>408 micromol/L
| participants | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| Creatinine >=150 micromol/L (Adults) | 0 | 0 | 0 | 1 |
| Creatinine >=30% change from baseline | 3 | 3 | 6 | 5 |
| Creatinine >=100% change from baseline | 0 | 0 | 0 | 0 |
| Creatinine Clearance <15 mL/min | 0 | 0 | 0 | 0 |
| Creatinine clearance >=15 to <30 mL/min | 0 | 0 | 0 | 0 |
| Creatinine clearance >=30 to <60 mL/min | 6 | 6 | 6 | 5 |
| Creatinine clearance >=60 to <90 mL/min | 8 | 7 | 15 | 17 |
| Blood Urea Nitrogen >=17 mmol/L | 0 | 0 | 0 | 0 |
| Uric acid <120 micromol/L | 0 | 1 | 0 | 0 |
| Uric acid >408 micromol/L | 1 | 1 | 2 | 4 |
Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN * Conjugated bilirubin(CBILI): \>1.5 ULN * Unconjugated bilirubin: \>1.5 ULN * ALT \>3 ULN and TBILI \>2 ULN * CBILI \>35% TBILI and TBILI \>1.5 ULN * Albumin: \<=25 g/L
| participants | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w |
|---|---|---|---|---|
| ALT >1 ULN and <=1.5 ULN | 3 | 4 | 7 | 6 |
| ALT >1.5 ULN and <=3 ULN | 2 | 1 | 3 | 2 |
| ALT >3 ULN and <=5 ULN | 1 | 0 | 1 | 4 |
| ALT >5 ULN and <=10 ULN | 1 | 0 | 0 | 0 |
| ALT >10 ULN and <=20 ULN | 0 | 0 | 0 | 0 |
| ALT >20 ULN | 0 | 0 | 0 | 0 |
| AST >1 ULN and <=1.5 ULN | 6 | 5 | 8 | 4 |
| AST >1.5 ULN and <=3 ULN | 1 | 0 | 2 | 3 |
| AST >3 ULN and <=5 ULN | 1 | 0 | 0 | 1 |
| AST >5 ULN and <=10 ULN | 0 | 0 | 0 | 0 |
| AST >10 ULN and <=20 ULN | 0 | 0 | 0 | 0 |
| AST >20 ULN | 0 | 0 | 0 | 0 |
| Alkaline Phosphatase >1.5 ULN | 0 | 0 | 0 | 0 |
| TBILI >1.5 ULN | 1 | 1 | 0 | 0 |
| TBILI >2 ULN | 0 | 0 | 0 | 0 |
| CBILI >1.5 ULN | 0 | 0 | 0 | 0 |
| Unconjugated Bilirubin >1.5 ULN | 0 | 0 | 0 | 0 |
| ALT> 3 ULN and TBILI >2ULN | 0 | 0 | 0 | 0 |
| CBILI >35% TBILI and TBILI >1.5 ULN | 0 | 0 | 0 | 0 |
| Albumin <=25 g/L | 0 | 0 | 0 | 0 |
Collected over All AEs were collected from signature of the informed consent form until the end of the study (Week 58) regardless of seriousness or relationship to IMP.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sarilumab 150 mg q2w + DMARDs | 0/15 (0%) | 0/15 (0%) | 14/15 (93.3%) |
| Sarilumab 200 mg q2w + DMARDs | 0/15 (0%) | 3/15 (20%) | 13/15 (86.7%) |
| Sarilumab 150 mg q2w Monotherapy | 0/30 (0%) | 1/30 (3.3%) | 22/30 (73.3%) |
| Sarilumab 200 mg q2w Monotherapy | 0/31 (0%) | 2/31 (6.5%) | 23/31 (74.2%) |
| Event | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w Monotherapy | Sarilumab 200 mg q2w Monotherapy |
|---|---|---|---|---|
| Chronic sinusitisInfections and infestations | 0/15 | 1/15 | 0/30 | 0/31 |
| Periorbital abscessInfections and infestations | 0/15 | 1/15 | 0/30 | 0/31 |
| Breast cancer femaleNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 1/15 | 0/30 | 0/31 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 1/15 | 0/30 | 0/31 |
| Herpes zoster oticusInfections and infestations | 0/15 | 0/15 | 1/30 | 0/31 |
| Pneumonia bacterialInfections and infestations | 0/15 | 0/15 | 0/30 | 1/31 |
| Abortion inducedSurgical and medical procedures | 0/15 | 0/15 | 0/30 | 1/31 |
| Event | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w Monotherapy | Sarilumab 200 mg q2w Monotherapy |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/15 | 5/15 | 13/30 | 14/31 |
| NeutropeniaBlood and lymphatic system disorders | 5/15 | 3/15 | 1/30 | 3/31 |
| StomatitisGastrointestinal disorders | 3/15 | 4/15 | 3/30 | 4/31 |
| ContusionInjury, poisoning and procedural complications | 3/15 | 0/15 | 2/30 | 0/31 |
| Injection site erythemaGeneral disorders | 0/15 | 1/15 | 1/30 | 6/31 |
| GastroenteritisInfections and infestations | 2/15 | 0/15 | 1/30 | 1/31 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/15 | 0/15 | 4/30 | 2/31 |
| DizzinessNervous system disorders | 0/15 | 2/15 | 2/30 | 1/31 |
| Hepatic function abnormalHepatobiliary disorders | 1/15 | 0/15 | 1/30 | 4/31 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/15 | 0/15 | 3/30 | 2/31 |
Modified intent-to-treat (mITT) population included all randomized participants who received at least one dose of investigational medicinal product (IMP), irrespective of compliance with the study protocol and procedures.
| Age, Continuous(years) | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Total |
|---|---|---|---|---|---|
| Mean | 56.3 ± 10.9 | 63.3 ± 10.6 | 54.4 ± 13.8 | 52.5 ± 10.3 | 55.6 ± 12.1 |
| Sex: Female, Male(Participants) | Sarilumab 150 mg q2w + DMARDs | Sarilumab 200 mg q2w + DMARDs | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Total |
|---|---|---|---|---|---|
| Female | 12 | 13 | 27 | 26 | 78 |
| Male | 3 | 2 | 3 | 5 | 13 |
The record gives a start of Feb 2015, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2018, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab